行情

NBIX

NBIX

神经分泌生物科学
NASDAQ

实时行情|Nasdaq Last Sale

101.09
-0.32
-0.32%
交易中 14:13 09/18 EDT
开盘
101.49
昨收
101.41
最高
102.23
最低
100.46
成交量
35.14万
成交额
--
52周最高
125.59
52周最低
64.72
市值
92.58亿
市盈率(TTM)
757.23
分时
5日
1月
3月
1年
5年

分析师评级

19位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NBIX 新闻

  • Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
  • Zacks.3小时前
  • Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
  • PR Newswire.21小时前
  • Neurocrine Biosciences Highlights Will Present Data On INGREZZA For Tardive Dyskinesia, Opicapone, VY-AADC For Parkinson's At International Congress of Parkinson's Disease and Movement Disorders
  • Benzinga.21小时前
  • Three Q4'19 Catalysts For Axovant
  • Seeking Alpha - Article.1天前

更多

所属板块

生物技术和医学研究
-1.42%
制药与医学研究
-0.43%

热门股票

名称
价格
涨跌幅

NBIX 简况

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
展开

Webull提供Neurocrine Biosciences, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。